Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Casein kinase I isoform delta (CK1 delta) is a member of the highly conserved serine/threonine protein kinase family that plays a pivotal role in regulating the eukaryotic circadian clock (UniProt: P48730). It phosphorylates Period proteins (PER1, PER2, and PER3), marking them for ubiquitination and proteasomal degradation, which is essential for maintaining the ~24-hour rhythm (Toh et al., Science, 2001). Beyond chronobiology, CK1 delta is involved in diverse cellular processes including DNA damage repair, Wnt/beta-catenin signaling, and microtubule dynamics (Knippschild et al., Cell Signal, 2005). Dysregulation of this kinase is linked to various pathologies; for instance, mutations in the CSNK1D gene cause Familial Advanced Sleep Phase Syndrome (FASPS), while its overexpression is observed in several cancers, including breast, pancreatic, and colon cancer (Cheong & Virshup, J Biochem, 2011). In neurodegenerative diseases like Alzheimer's and ALS, CK1 delta is implicated in the pathological phosphorylation of tau and TDP-43 (Xu et al., Int J Mol Sci, 2019). Pharmacological targeting of CK1 delta focuses on small-molecule inhibitors that compete for the ATP-binding pocket, such as PF-670462, though achieving selectivity over the closely related CK1 epsilon isoform remains a significant therapeutic challenge (Janovska et al., Br J Pharmacol, 2020).
ATP-competitive inhibition of the kinase domain to prevent phosphorylation of downstream substrates such as PER proteins and p53 (Janovska et al., Br J Pharmacol, 2020).
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Casein kinase I isoform delta (CSNK1D) (CSNK1D).